A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...
HER2, a HER2-targeted immunotherapy, with plans for FDA submission following promising Phase 2b data in osteosarcoma.
The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...
The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
Stocktwits on MSN2d
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage UniverseValuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in ...
GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...
Scientists have developed new light-sensitive chemicals that can radically improve the treatment of aggressive cancers with ...
Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...
Treatment uses electric pulses to kill prostate cancer cells while minimising risks of incontinence and sexual dysfunction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback